Lawrence W Wise

US Patent:

6642398, Nov 4, 2003

Filed:

Dec 20, 2002

Appl. No.:

10/324929

Inventors:

Thomas Richard Belliotti - Saline MI
Justin Stephen Bryans - Balsham, GB
Ihoezo Victor Ekhato - West Chester PA
Augustine Tobi Osuma - Ann Arbor MI
Robert Michael Schelkun - Ypsilanti MI
Jacob Bradley Schwarz - Ann Arbor MI
Andrew John Thorpe - Ann Arbor MI
Lawrence David Wise - Ann Arbor MI
David Juergen Wustrow - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

C07D 1000

US Classification:

554108, 554103, 514557, 514558, 514559, 514560, 514740, 514741, 562433, 562512, 562553, 564453, 564454, 564463, 564503, 564509

Abstract:

The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.

US Patent:

6765022, Jul 20, 2004

Filed:

Dec 2, 2002

Appl. No.:

10/297055

Inventors:

Russell Joseph Deorazio - Schnectady NY
Sham Shridhar Nikam - Ann Arbor MI
Ian Leslie Scott - Delanson NY
Brian Alan Sherer - Clifton Park NY
Lawrence David Wise - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31137

US Classification:

514646, 514649, 514651, 514653, 514654, 564342, 564344, 564345, 564347, 564348, 564355, 564360, 564366, 564374, 564383

Abstract:

Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinsons disease. The substituents are described in the specification.

US Patent:

6794402, Sep 21, 2004

Filed:

Nov 12, 2002

Appl. No.:

10/276054

Inventors:

Sham Shridhar Nikam - Ann Arbor MI
Ian Leslie Scott - Delanson NY
Brian Alan Sherer - Ballston Spa NY
Lawrence David Wise - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31423

US Classification:

514375, 548221

Abstract:

Described are bicycle-substituted cyclohexylamines of Formula I and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinsons disease. The substituents are defined in the specification.

US Patent:

20040063789, Apr 1, 2004

Filed:

Sep 29, 2003

Appl. No.:

10/674192

Inventors:

Thomas Belliotti - Saline MI, US
Justin Bryans - Balsham, GB
Ihoezo Ekhato - West Chester PA, US
Augustine Osuma - Canton MI, US
Robert Schelkun - Milan MI, US
Jacob Schwarz - Ann Arbor MI, US
Andrew Thorpe - Ann Arbor MI, US
Lawrence Wise - Ann Arbor MI, US
David Wustrow - Ann Arbor MI, US

International Classification:

A61K031/195

US Classification:

514/561000, 514/567000

Abstract:

The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.

US Patent:

61878081, Feb 13, 2001

Filed:

Sep 27, 1999

Appl. No.:

9/402046

Inventors:

Stephen Joseph Johnson - Ann Arbor MI
Leonard Theodore Meltzer - Ann Arbor MI
Lawrence David Wise - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3115
A61K 31381
C07C25134
C07C25174
C07D33302

US Classification:

514438

Abstract:

This invention provides 6-amino-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one oximes and hydrazones which are useful in treating Parkinson's disease.

US Patent:

47925485, Dec 20, 1988

Filed:

May 21, 1986

Appl. No.:

6/865306

Inventors:

Horace A. DeWald - Ann Arbor MI
Lawrence D. Wise - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31535
C07D49804

US Classification:

5142298

Abstract:

trans-Benzopyran-4,3b-1,4-oxazines are described as well as methods of preparation. The compounds are presynaptic dopamine agonists and may be used in pharmaceutical composition form for treating psychoses, e. g. , schizophrenia.

US Patent:

48032034, Feb 7, 1989

Filed:

Jun 16, 1987

Appl. No.:

7/062752

Inventors:

Bradley W. Caprathe - Redford MI
Horace A. DeWald - Ann Arbor MI
Juan C. Jaen - Plymouth MI
Lawrence D. Wise - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31495
A61K 31535
C07D40512
C07D41314

US Classification:

5142305

Abstract:

Novel phenyl and heterocyclic tetrahydropyridyl and piperazinyl alkoxy benzheterocyclic compounds are described which have valuable neuroleptic properties by virture of their dopamine autoreceptor agonist activity. Methods of preparation, pharmeceutical compositions, and methods for treating psychoses, such a schizophrenia, are also described.

US Patent:

59169141, Jun 29, 1999

Filed:

Aug 8, 1997

Appl. No.:

8/907680

Inventors:

David Thomas Connor - Ann Arbor MI
Stephen Joseph Johnson - Ann Arbor MI
Suzanne Ross Kesten - Ann Arbor MI
Steven Robert Miller - Ann Arbor MI
Paul Charles Unangst - Ann Arbor MI
Lawrence David Wise - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3135
C07D31102
C07D31912

US Classification:

514456

Abstract:

This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.